Nuclear pharmacy is rapidly moving from the background to the forefront of oncology care.

In this season finale episode, Nic Mastiscusa, PharmD, Chief Nuclear Pharmacist at the University of Iowa Hospitals and Clinics, breaks down how theranostics and radiopharmaceutical therapies are changing the way certain cancers are diagnosed and treated. Nick explains how targeted radioactive drugs can both locate tumors and deliver therapy, what this means for diseases like neuroendocrine tumors and prostate cancer, and why concepts such as alpha vs. beta emitters and dosimetry matter clinically.

This episode is ACPE-accredited for pharmacists and pharmacy technicians and is worth 0.5 credit.

Learning Objectives

• Describe the role of nuclear pharmacy and theranostics in oncology care
• Differentiate between diagnostic and therapeutic radiopharmaceuticals
• Explain clinical differences between alpha- and beta-emitting radiopharmaceuticals
• Identify the role of dosimetry in personalized radiopharmaceutical treatment
• Recognize key patient counseling and safety considerations related to radiopharmaceutical therapies

CE Information
This activity is ACPE accredited for pharmacists and pharmacy technicians.
CE credit is available upon successful completion of the post-activity requirements.

Access the CE activity here:
https://www.lecturepanda.com/r/PQIPodcastTheranostics

CE Disclosures
Nic Mastascusa, PharmD, R.Ph., BCNP discloses affiliations with NMTCB and NANP.